Keyphrases
Multiple Sclerosis
100%
Disease-modifying Therapy
81%
National Cohort Study
53%
Confidence Interval
50%
Expanded Disability Status Scale
44%
Hazard Ratio
30%
Low Risk
25%
Treatment Escalation
22%
Previously Treated
22%
Effective Therapy
22%
Pediatric multiple Sclerosis
22%
Neutralizing Antibodies
22%
Glatiramer Acetate
22%
High Efficacy Disease-modifying Therapies
22%
Interferon-α (IFN-α)
22%
Highly Effective
22%
Clinical Outcome Prediction
22%
Disease Activity
22%
Clinically Stable
22%
Disability Pension
22%
Early-late
22%
Comparative Effectiveness
22%
Stable Disease
22%
Late Treatment
22%
Dimethyl Fumarate
22%
Register Study
22%
Income Loss
22%
Teriflunomide
22%
Annualized Relapse Rate
17%
First Relapse
15%
Multiple Sclerosis Treatment
14%
Treatment Outcome
14%
Disability Worsening
13%
Relapse Rate
11%
Disease Duration
11%
Disease Course
11%
Early Treatment
10%
Salary
9%
Reduced Rate
9%
Disability Improvement
9%
Early Treated
9%
Follow-up Time
8%
Treatment Efficacy
8%
Cox Proportional Hazards Model
7%
Propensity Score Matching
7%
Activity Groups
6%
Risk Reduction
6%
T2 Lesions
5%
Rate Ratio
5%
Birthday
5%
Medicine and Dentistry
Multiple Sclerosis
86%
Disease Modifying Therapy
63%
Disease
46%
Cohort Analysis
45%
Recurrence Risk
34%
Disability Pension
22%
Pediatrics
22%
Fumaric Acid Dimethyl Ester
22%
Teriflunomide
22%
Expanded Disability Status Scale
22%
Combination Therapy
9%
Disease Course
6%
Disease Duration
5%
Hazard Ratio
5%
Propensity Score Matching
5%
